An2 Therapeutics, INC Form 4 insider transactions

AN2 Therapeutics Director Patricia A. Martin was granted 20,400 stock options with an exercise price of $1.04, vesting in February 2027.

AN2 Therapeutics Director Melvin K. Spigelman acquired 20,400 stock options with an exercise price of $1.04, vesting on February 20, 2027.

AN2 Therapeutics Director Kabeer Aziz was granted 20,400 stock options with an exercise price of $1.04, vesting on February 20, 2027.

AN2 Therapeutics Director Margaret M. FitzPatrick was granted 20,400 stock options with an exercise price of $1.04, vesting in February 2027.

AN2 Therapeutics Director Joseph S. Zakrzewski was granted 20,400 stock options with an exercise price of $1.04.

AN2 Therapeutics Director Kabeer Aziz acquired 11,560 shares of common stock on January 12, 2026, as part of his non-employee director compensation.

AN2 Therapeutics Director Patricia A. Martin acquired 3,650 shares of common stock as non-cash compensation, increasing her total beneficial ownership to 16,905 shares.

AN2 Therapeutics Director Gilbert Lynn Marks received 11,560 shares of common stock as non-employee director compensation.

AN2 Therapeutics' Chief Financial Officer, Lucy Day, sold shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

AN2 Therapeutics' Chief Strategy Officer, Stephen David Prior, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

AN2 Therapeutics' Chief Development Officer, Sanjay Chanda, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

AN2 Therapeutics' Chief Operating Officer and Chief Legal Officer, Joshua M. Eizen, sold shares of common stock to cover tax withholding obligations from RSU vesting.

AN2 Therapeutics' Chief Operating Officer, Joshua M. Eizen, sold 2,819 shares of common stock to cover tax withholding obligations related to RSU vesting.

Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, sold 765 shares of common stock to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

AN2 Therapeutics director Gilbert Lynn Marks received 10,367 shares of common stock as non-cash compensation, increasing his direct beneficial ownership to 63,749 shares.

AN2 Therapeutics director Kabeer Aziz acquired 10,367 shares of common stock as non-cash compensation, increasing his direct beneficial ownership.

AN2 Therapeutics Director Patricia A. Martin acquired 3,274 shares of common stock as equity compensation, increasing her total beneficial ownership to 13,255 shares.

AN2 Therapeutics, Inc. Director Kabeer Aziz acquired 11,875 shares of common stock on July 10, 2025, as non-cash compensation, increasing his total beneficial ownership.

AN2 Therapeutics Director Gilbert Lynn Marks acquired 11,875 shares of common stock on July 10, 2025, as non-cash compensation, increasing his total beneficial ownership to 53,382 shares.

AN2 Therapeutics Director Patricia A. Martin received 3,750 shares of common stock on July 10, 2025, as non-cash compensation, increasing her total beneficial ownership to 9,981 shares.

Braden Michael Leonard, a Director and 10% owner of AN2 Therapeutics, Inc. (ANTX), reported the sale of 200,000 shares of common stock at $1.09 per share.

AN2 Therapeutics, Inc. CEO Eric Easom has purchased 10,000 shares of common stock at an average price of $1.0665, increasing his direct beneficial ownership.

Braden Michael Leonard, a Director and 10% owner of AN2 Therapeutics, Inc., has reported the sale of 2,532,000 shares of common stock for approximately $2.87 million in late May 2025.

AN2 Therapeutics, Inc. Director Margaret M. FitzPatrick has purchased 8,610 shares of common stock, signaling increased insider confidence in the company.

AN2 Therapeutics, Inc. Director Robin Shane Readnour was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

AN2 Therapeutics, Inc. Director Patricia A. Martin was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

AN2 Therapeutics, Inc. Director Margaret M. FitzPatrick was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

AN2 Therapeutics, Inc. Director Joseph S. Zakrzewski was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

AN2 Therapeutics, Inc. Director Melvin K. Spigelman was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

AN2 Therapeutics, Inc. Director Stephanie Wong reported the acquisition of 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.